Oxidative stress and mitochondrial dysfunction in down syndrome

Advances in Experimental Medicine and Biology

Volumn 724, Issue , 2012, Pages 291-299

  Pagano, Giovanni ^a   Castello, Giuseppe ^a  

^a CROM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMYLOID PRECURSOR PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME C OXIDASE; ISOCITRATE DEHYDROGENASE; LEVACECARNINE; MENADIONE; PYRUVATE DEHYDROGENASE; RESVERATROL; ROTENONE; SIRTUIN; THIOCTIC ACID; UBIDECARENONE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL MATURATION; CELLULAR IMMUNODEFICIENCY; CHROMOSOME 21; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN SYNDROME; DRUG EFFECT; GENE LOCATION; HUMAN; LYMPHOCYTE FUNCTION; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROPATHOLOGY; NITROSATIVE STRESS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRISOMY 16; ULTRASTRUCTURE; UPREGULATION; ANIMAL; GENETICS; METABOLISM; MITOCHONDRION; MOUSE; PATHOLOGY; PHYSIOLOGY; REVIEW;

MUS;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; HUMANS; MICE; MITOCHONDRIA; MITOCHONDRIAL DISEASES; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE;

EID: 84859508314     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0653-2_22     Document Type: Article

References (75)

1. Hayes A, Batshaw ML. Down syndrome. Pediatr Clin North Am 1993; 40:523-535.
2. Musiani P, Valitutti S, Castellino F et al. Intrathymic deficient expansion of T-cell precursors in Down syndrome. Am J Med Genet Suppl 1990; 7:219-224.
3. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001;2:429-436.
4. Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev 2001; 7:172-178.
5. Brooksbank BW, Balasz R. Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Exp Brain Res 1984; 16:37-44.
6. Kedziora J, Bartosz G. Down's syndrome: A pathology involving the lack of balance of reactive oxygen species. Free Rad Biol Med 1988; 4:317-330.
7. Groner Y, Elroy-Stein O, Avraham KB et al. Cell damage by excess CuZnSOD and Down's syndrome. Biomed Pharmacother 1994; 48:231-240.
8. Busciglio J, Yankner BA. Apoptosis and increased generation ofreactive oxygen species in Down's syndrome neurons in vitro. Nature 1995; 378:776-779.
9. Balcz B, Kirchner L, Cairns N et al. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm Suppl 2001; 61:193-201.
10. Epstein CJ, Avraham KB, Lovett M et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: Animal model of dosage effects in Down syndrome. Proc Natl Acad Sci USA 1987; 84:8044-8048.
11. Muchova J, Sustrova M, Garaiova I et al. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med 2001; 31:499-508.
12. Garaiova I, Muchova J, Sustrova M et al. The relationship between antioxidant systems and some markers of oxidative stress in persons with Down syndrome. Biologia (Bratislava) 2004; 59:781-788.
13. Slonim DK, Koide K, Johnson KL et al. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc Natl Acad Sci USA 2009; 106:9425-9429.
14. Conti A, Fabbrini F, D'Agostino P et al. Altered expression of mitochondrial and extracellular matrix genes in the heart ofhuman fetuses with chromosome 21 trisomy. BMC Genomics 2007; 8:268.
15. Pastor MC, Sierra C, Dolade M et al. Antioxidant enzymes and fatty acid status in erythrocytes of Down's syndrome patients. Clin Chem 1998; 44:924-929.
16. Garcez ME, Peres W, Salvador M. Oxidative stress and hematologic and biochemical parameters in individuals with Down syndrome. Mayo Clin Proc 2005; 80:1607-1611.
17. Casado A, Lopez-Fernandez ME, RuizR. Lipid peroxidation in Down syndrome caused by regular trisomy 21,trisomy21 byRobertsoniantranslocationandmosaictrisomy21. ClinChemLabMed2007;45:59-62.
18. Pallardo FV, Degan P, d'Ischia M et al. Higher age-related prooxidant state in young Down syndrome patients indicates accelerated aging. Biogerontology 2006; 7:211-220.
19. Zana M, Szecsenyi A, Czibula A et al. Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem Biophys Res Commun. 2006; 345:726-733.
20. Zitnanova I, Korytar P, Aruoma OI et al. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clin Chim Acta 2004; 341:139-146.
21. Uberos J, Romero J, Molina-Carballo A et al. Melatonin and elimination of kynurenines in children with Down's syndrome. J Pediatr Endocrinol Metab 2010; 23:277-282.
22. Coppus AM, Fekkes D, Verhoeven WM et al. Plasma levels of nitric oxide related amino acids in demented subjects with Down syndrome are related to neopterin concentrations. Amino Acids 2010; 38:923-928.
23. Nagyova A, Sustrova M, Raslova K. Serum lipid resistance to oxidation and uric acid levels in subjects with Down's syndrome. Physiol Res 2000; 49:227-231.
24. Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 1998; 25:1044-1048.
25. Pratico D, Iuliano L, Amerio G et al. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 2000; 48:795-798.
26. Perrone S, Longini M, Bellieni CV et al. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin Biochem 2007; 40:177-180.
27. Miller ME, Mellman Cohen MM, Kohn G et al. Depressed immunoglobulin G in newborn infants with Down's syndrome. J Pediatr 1969; 75:996-1000.
28. Lopez V. Serum IgE concentration in trisomy 21. J Ment Defic Res 1974; 18:111-114.
29. Burgio GR, Lanzavecchia A, Maccario R et al. Immunodeficiency in Down's syndrome: T-lymphocyte subset imbalance in trisomic children. Clin Exp Immunol 1978; 33:298-301.
30. Mrak RE, Griffin WS. Trisomy 21 and the brain. J Neuropathol Exp Neurol. 2004; 63:679-685.
31. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 2006; 83:470S-474S.
32. Shimada A, Hayashi Y, Ogasawara M et al. Pro-inflammatory cytokinemia is frequently found in Down syndrome patients with hematological disorders. Leuk Res 2007; 31:1199-1203.
33. Guazzarotti L, Trabattoni D, Castelletti E et al. T-lymphocyte maturation is impaired in healthy young individuals carrying trisomy 21 (Down syndrome). Am J Intellect Dev Disabil 2009; 114:100-109.
34. Cetiner S, Demirhan O, Inal TC et al. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. Int J Immunogenet 2010; 37:233-237.
35. Bloemers BL, van Bleek GM, Kimpen JL et al. Distinct abnormalities in the innate immune system of children with Down syndrome. J Pediatr 2010; 156:804-809.
36. Costa V, Sommese L, Casamassimi A et al. Impairment of circulating endothelial progenitors in Down syndrome. BMC Med Genomics 2010; 3:40.
37. Roberts RA, Smith RA, Safe S et al. Toxicological and pathophysiological roles of reactive oxygen and nitrogen species. Toxicology 2010; 276:85-94.
38. Candore G, Bulati M, Caruso C et al. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res 2010; 13:301-313.
39. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med 2010; 4:27-36.
40. Prince J, Jia S, Bave U et al. Mitochondrial enzyme deficiencies in Down's syndrome. J Neural Transm Park Dis Dement Sect 1994; 8:171-181.
41. Bersu ET, Ahmad FJ, Schwei MJ et al. Cytoplasmic abnormalities in cultured cerebellar neurons from the trisomy 16 mouse. Brain Res Dev Brain Res 1998; 109:115-120.
42. Schuchmann S, HeinemannU. Increased mitochondrial superoxide generation in neurons from trisomy 16 mice: a model ofDown's syndrome. Free Radic Biol Med 2000; 28:235-250.
43. Capone G, Kim P, Jovanovich S et al. Evidence for increased mitochondrial superoxide production in Down syndrome. Life Sci 2002; 70:2885-2895.
44. BambrickLL,FiskumG.Mitochondrialdysfunctioninmouse trisomy 16 brain. Brain Res 2008; 1188:9-16.
45. Busciglio J, Pelsman A, Wong C et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 2002; 33:677-688.
46. Druzhyna N, Nair RG, LeDoux SP et al. Defective repair of oxidative damage in mitochondrial DNA in Down's syndrome. Mutat Res 1998; 409:81-89.
47. Conti A, Fabbrini F, D'Agostino P et al. Altered expression of mitochondrial and extracellular matrix genes in the heart ofhuman fetuses with chromosome 21 trisomy. BMC Genomics 2007; 8:268.
48. Roat E, Prada N, Ferraresi R et al. Mitochondrial alterations and tendency to apoptosis in peripheral blood cells from childrenwith Down syndrome. FEBS Lett 2007; 581:521-525.
49. Pallardo FV, Lloret A, Lebel M et al. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down syndrome, Fanconi Anaemia and Werner syndrome. Biogerontology 2010; 11:401-419.
50. Harman D. Alzheimer's disease pathogenesis: role of aging. Ann NY Acad Sci 2006; 1067:454-460.
51. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004; 82:510-529.
52. McCay CM, Crowell MF, Maynard LA. The effect of retarded growth upon the length of life span and upon the ultimate body size. J Nutrition 1935; 10:63-79.
53. Csiszar A, Labinskyy N, Podlutsky A et al. Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol 2008; 294:H2721-H2735.
54. Baur JA, Pearson KJ, Price NL et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337-342.
55. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res 2008; 33:194-203.
56. Palaniappan AR, Dai A. Mitochondrial ageing and the beneficial role of alpha-lipoic acid. Neurochem Res 2007; 32:1552-1558.
57. Plecita-Hlavata L, Jezek J, Jezek P. Pro-oxidant mitochondrial matrix-targeted ubiquinone MitoQ10 acts as anti-oxidant at retarded electron transport or proton pumping within Complex I. Int J Biochem Cell Biol 2009; 41:1697-1707.
58. Long J, Wang X, Gao H et al. D-galactose toxicity in mice is associated with mitochondrial dysfunction: protecting effects of mitochondrial nutrient R-alpha-lipoic acid. Biogerontology 2007; 8:373-381.
59. Gadaleta MN, Petruzzella V, Renis M et al. Reduced transcription of mitochondrial DNA in the senescent rat. Tissue dependence and effect of L-carnitine. Eur J Biochem 1990; 187:501-506.
60. Traina G, Federighi G, Brunelli M et al. Cytoprotective effect of acetyl-L-carnitine evidenced by analysis of gene expression in the rat brain. Mol Neurobiol 2009; 39:101-106.
61. Madiraju P, Pande SV, Prentki M et al. Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. Epigenetics 2009; 4:399-403.
62. Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: is acetylcarnitine a rejuvenator? Adv Drug Deliv Rev 2009; 61:1332-1342.
63. Rodriguez MC, Macdonald JR, Mahoney DJ et al. Beneficial effects of creatine, CoQ10 and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35:235-242.
64. Savitha S, Panneerselvam C. Mitigation of age-dependent oxidative damage to DNA in rat heart by carnitine and lipoic acid. Mech Ageing Dev 2007; 128:206-212.
65. Maroz A, Anderson RF, Smith RAJ et al. Reactivity of ubiquinone and ubiquinol with superoxide and the hydroperoxyl radical: implications for in vivo antioxidant activity. Free Radic Biol Med 2009;46:105-109.
66. Miles MV, Patterson BJ, Chalfonte-Evans ML et al. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr Neurol 2007; 37:398-403.
67. Tiano L, Carnevali P, Padella L et al. Effect of Coenzyme Q(10) in mitigating oxidative DNA damage in Down syndrome patients, a double blindrandomized controlled trial. Neurobiol Aging 2009; doi:10.1016/j. neurobiolaging.2009.11.016.
68. Kaufmann P, Thompson JL, Levy G et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009; 66:235-244.
69. Storch A, Jost WH, Vieregge P et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007; 64:938-944.
70. Caso G, Kelly P, McNurlan MA et al. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99:1409-1412.
71. Palacka P, Kucharska J, Murin J et al. Complementary therapy in diabetic patients with chronic complications: a pilot study. Bratisl Lek Listy 2010; 111:205-211.
72. Hertz N, Lister RE. Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study. J Int Med Res 2009; 37:1961-1971.
73. Tarnopolsky MA. The mitochondrial cocktail: rationale for combinednutraceutical therapy inmitochondrial cytopathies. Adv Drug Deliv Rev 2008; 60:1561-1567.
74. Vila M, Ramonet D, Perier C. Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem 2008; 107:317-328.
75. Wang X, Su B, Lee HG et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 2009; 28:9090-9103.